Modulation of the poliovirus receptor function
A molecule specifically binding to at least one intra- or extracellular domain of the CD155 (cluster of differentiation 155), the poliovirus receptor (PVR), or any of their derivatives, where the molecule has the ability to modulate a receptor mediated adhesion, trafficking and/or invasion behavior...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | CAROLIN ZEHETMEIER CHRISTINE MARGARETE UNGER GERALD BESTE BRENDA K. EUSTACE DANIEL G. JAY KEVIN ERNEST SLOAN CLAUDIA TORELLA BLANCA LAIN |
description | A molecule specifically binding to at least one intra- or extracellular domain of the CD155 (cluster of differentiation 155), the poliovirus receptor (PVR), or any of their derivatives, where the molecule has the ability to modulate a receptor mediated adhesion, trafficking and/or invasion behavior of a cell expressing the CD155, the PVR, or any derivatives, is new. Independent claims are also included for the following: (1) a method of identifying and isolating the above molecule; (2) a nucleic acid molecule encoding the molecule cited above, or the ligand identified by the above method; (3) a vector comprising the above nucleic acid molecule; (4) a pharmaceutical composition comprising the above molecule, the molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and/or a pharmaceutical carrier and/or diluent; (5) methods of modulating ex vivo the adhesion or invasion behavior of a cell expressing CD155, PVR or any of their derivatives; (6) a method of treating or preventing proliferative disorder or disease, cancer and/or metastasis; (7) a kit comprising the above molecule, molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and suitable testing containers; and (8) a method of detecting and/or isolating cells expressing CD155, PVR or any derivatives. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Gene therapy. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2004213150A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2004213150A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2004213150A13</originalsourceid><addsrcrecordid>eNrjZNDzzU8pzUksyczPU8hPUyjJSFUoyM_JzC_LLCotVihKTU4tKMkvUkgrzUsGqeFhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGOoUYGBiZGhsaGpgaOhsbEqQIA1J8rwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Modulation of the poliovirus receptor function</title><source>esp@cenet</source><creator>CAROLIN ZEHETMEIER ; CHRISTINE MARGARETE UNGER ; GERALD BESTE ; BRENDA K. EUSTACE ; DANIEL G. JAY ; KEVIN ERNEST SLOAN ; CLAUDIA TORELLA ; BLANCA LAIN</creator><creatorcontrib>CAROLIN ZEHETMEIER ; CHRISTINE MARGARETE UNGER ; GERALD BESTE ; BRENDA K. EUSTACE ; DANIEL G. JAY ; KEVIN ERNEST SLOAN ; CLAUDIA TORELLA ; BLANCA LAIN</creatorcontrib><description>A molecule specifically binding to at least one intra- or extracellular domain of the CD155 (cluster of differentiation 155), the poliovirus receptor (PVR), or any of their derivatives, where the molecule has the ability to modulate a receptor mediated adhesion, trafficking and/or invasion behavior of a cell expressing the CD155, the PVR, or any derivatives, is new. Independent claims are also included for the following: (1) a method of identifying and isolating the above molecule; (2) a nucleic acid molecule encoding the molecule cited above, or the ligand identified by the above method; (3) a vector comprising the above nucleic acid molecule; (4) a pharmaceutical composition comprising the above molecule, the molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and/or a pharmaceutical carrier and/or diluent; (5) methods of modulating ex vivo the adhesion or invasion behavior of a cell expressing CD155, PVR or any of their derivatives; (6) a method of treating or preventing proliferative disorder or disease, cancer and/or metastasis; (7) a kit comprising the above molecule, molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and suitable testing containers; and (8) a method of detecting and/or isolating cells expressing CD155, PVR or any derivatives. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Gene therapy.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040902&DB=EPODOC&CC=AU&NR=2004213150A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040902&DB=EPODOC&CC=AU&NR=2004213150A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CAROLIN ZEHETMEIER</creatorcontrib><creatorcontrib>CHRISTINE MARGARETE UNGER</creatorcontrib><creatorcontrib>GERALD BESTE</creatorcontrib><creatorcontrib>BRENDA K. EUSTACE</creatorcontrib><creatorcontrib>DANIEL G. JAY</creatorcontrib><creatorcontrib>KEVIN ERNEST SLOAN</creatorcontrib><creatorcontrib>CLAUDIA TORELLA</creatorcontrib><creatorcontrib>BLANCA LAIN</creatorcontrib><title>Modulation of the poliovirus receptor function</title><description>A molecule specifically binding to at least one intra- or extracellular domain of the CD155 (cluster of differentiation 155), the poliovirus receptor (PVR), or any of their derivatives, where the molecule has the ability to modulate a receptor mediated adhesion, trafficking and/or invasion behavior of a cell expressing the CD155, the PVR, or any derivatives, is new. Independent claims are also included for the following: (1) a method of identifying and isolating the above molecule; (2) a nucleic acid molecule encoding the molecule cited above, or the ligand identified by the above method; (3) a vector comprising the above nucleic acid molecule; (4) a pharmaceutical composition comprising the above molecule, the molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and/or a pharmaceutical carrier and/or diluent; (5) methods of modulating ex vivo the adhesion or invasion behavior of a cell expressing CD155, PVR or any of their derivatives; (6) a method of treating or preventing proliferative disorder or disease, cancer and/or metastasis; (7) a kit comprising the above molecule, molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and suitable testing containers; and (8) a method of detecting and/or isolating cells expressing CD155, PVR or any derivatives. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Gene therapy.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNDzzU8pzUksyczPU8hPUyjJSFUoyM_JzC_LLCotVihKTU4tKMkvUkgrzUsGqeFhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBYnJqXmpJfGOoUYGBiZGhsaGpgaOhsbEqQIA1J8rwQ</recordid><startdate>20040902</startdate><enddate>20040902</enddate><creator>CAROLIN ZEHETMEIER</creator><creator>CHRISTINE MARGARETE UNGER</creator><creator>GERALD BESTE</creator><creator>BRENDA K. EUSTACE</creator><creator>DANIEL G. JAY</creator><creator>KEVIN ERNEST SLOAN</creator><creator>CLAUDIA TORELLA</creator><creator>BLANCA LAIN</creator><scope>EVB</scope></search><sort><creationdate>20040902</creationdate><title>Modulation of the poliovirus receptor function</title><author>CAROLIN ZEHETMEIER ; CHRISTINE MARGARETE UNGER ; GERALD BESTE ; BRENDA K. EUSTACE ; DANIEL G. JAY ; KEVIN ERNEST SLOAN ; CLAUDIA TORELLA ; BLANCA LAIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2004213150A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2004</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>CAROLIN ZEHETMEIER</creatorcontrib><creatorcontrib>CHRISTINE MARGARETE UNGER</creatorcontrib><creatorcontrib>GERALD BESTE</creatorcontrib><creatorcontrib>BRENDA K. EUSTACE</creatorcontrib><creatorcontrib>DANIEL G. JAY</creatorcontrib><creatorcontrib>KEVIN ERNEST SLOAN</creatorcontrib><creatorcontrib>CLAUDIA TORELLA</creatorcontrib><creatorcontrib>BLANCA LAIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CAROLIN ZEHETMEIER</au><au>CHRISTINE MARGARETE UNGER</au><au>GERALD BESTE</au><au>BRENDA K. EUSTACE</au><au>DANIEL G. JAY</au><au>KEVIN ERNEST SLOAN</au><au>CLAUDIA TORELLA</au><au>BLANCA LAIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Modulation of the poliovirus receptor function</title><date>2004-09-02</date><risdate>2004</risdate><abstract>A molecule specifically binding to at least one intra- or extracellular domain of the CD155 (cluster of differentiation 155), the poliovirus receptor (PVR), or any of their derivatives, where the molecule has the ability to modulate a receptor mediated adhesion, trafficking and/or invasion behavior of a cell expressing the CD155, the PVR, or any derivatives, is new. Independent claims are also included for the following: (1) a method of identifying and isolating the above molecule; (2) a nucleic acid molecule encoding the molecule cited above, or the ligand identified by the above method; (3) a vector comprising the above nucleic acid molecule; (4) a pharmaceutical composition comprising the above molecule, the molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and/or a pharmaceutical carrier and/or diluent; (5) methods of modulating ex vivo the adhesion or invasion behavior of a cell expressing CD155, PVR or any of their derivatives; (6) a method of treating or preventing proliferative disorder or disease, cancer and/or metastasis; (7) a kit comprising the above molecule, molecules or ligands identified by the above method, the nucleic acid molecule or the vector, and suitable testing containers; and (8) a method of detecting and/or isolating cells expressing CD155, PVR or any derivatives. ACTIVITY : Cytostatic. No biological data given. MECHANISM OF ACTION : Gene therapy.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_AU2004213150A1 |
source | esp@cenet |
subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
title | Modulation of the poliovirus receptor function |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A56%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CAROLIN%20ZEHETMEIER&rft.date=2004-09-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2004213150A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |